Pfizer Stock Price, News & Analysis

Pfizer Inc. (NYSE: PFE) has commenced a Phase 1 clinical trial for a single dose quadrivalent mRNA influenza vaccine, targeting healthy adults. This innovative vaccine utilizes mRNA technology, which offers quicker manufacturing and potentially better efficacy compared to traditional vaccines. The trial aims to assess safety, tolerability, and immunogenicity. Influenza causes about 5 million severe illness cases and up to 650,000 deaths annually, highlighting the need for more effective vaccines. Pfizer plans to expand mRNA technology beyond influenza to other respiratory viruses and oncology.

Pfizer (NYSE: PFE) has initiated the Phase 2/3 EPIC-PEP trial, evaluating the oral antiviral PF-07321332, co-administered with ritonavir, for COVID-19 prevention among adults in close contact with infected individuals. This trial aims to enroll up to 2,660 participants to assess the drug's safety and efficacy in preventing SARS-CoV-2 infection. PF-07321332 is designed for early use, potentially before hospitalization is needed. The trial is part of a broader global study aiming to tackle COVID-19's ongoing impact.

Pfizer Inc. (NYSE: PFE) invites the public to a webcast of its conference call with investment analysts on November 2, 2021, at 10 a.m. EDT. The call will provide an update on Pfizer's Third Quarter 2021 Performance Report. Interested participants can register at www.pfizer.com/investors. The call will also be available via dial-in at (833) 708-1779 (U.S. and Canada) or (602) 585-9859 (international), with passcode “110221”. A transcript and replay will be accessible for 90 days post-event.

Pfizer Inc. (NYSE: PFE) announced a quarterly cash dividend of $0.39 per share for the fourth quarter of 2021. This dividend, which will be paid on December 6, 2021, marks the 332nd consecutive quarterly dividend payment by the company. Shareholders eligible for this payment must hold shares by the close of business on November 5, 2021.

Pfizer continues to demonstrate its commitment to returning value to shareholders through consistent dividend payments.

The FDA has granted Emergency Use Authorization (EUA) for a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 and older, as well as those aged 18-64 at high risk. The booster, to be administered at least six months after the primary series, is backed by clinical data demonstrating strong immune response against COVID-19 variants. The reactogenicity profile post-booster is mild to moderate, similar to the primary series. The vaccine continues to be supplied under existing agreements, with a commitment to provide two billion doses to lower-income countries by 2022.

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) expanded their agreement with the U.S. government to supply an additional 500 million COVID-19 vaccine doses for donation to low-income countries. This increases the total pledged doses to one billion, supporting the commitment to deliver two billion doses to low- and middle-income countries by the end of 2022. The doses are expected to be delivered by September 2022, with production at Pfizer facilities in the U.S.

Pfizer Inc. (NYSE: PFE) invites investors and the public to a webcast with CEO Albert Bourla at the Cantor Global Healthcare Conference on September 27, 2021, at 12:10 p.m. EDT. The webcast can be accessed on the Pfizer Investors website. A transcript and replay will be available within 24 hours and accessible for 90 days. Pfizer is committed to extending patient lives through innovative therapies and maintaining transparency with investors regarding its performance and strategies.

Pfizer (PFE) and BioNTech (BNTX) released results from a pivotal Phase 2/3 trial of their COVID-19 vaccine for children 5 to 11 years old. The study demonstrated a good safety profile and robust antibody responses after administering a 10 µg dose in a two-dose regimen. The vaccine's immune response was comparable to that seen in older populations. The companies plan to submit these data to the FDA and EMA for Emergency Use Authorization soon, with results for children under 5 expected later this year.

The FDA's Vaccines Advisory Committee has unanimously recommended the Emergency Use Authorization (EUA) for a COMIRNATY booster dose for individuals 65 and older and those at high risk for severe COVID-19. Data presented showed high neutralization titers against SARS-CoV-2 variants post-booster with a mild to moderate reactogenicity profile. Real-world evidence from Israel indicates that booster doses significantly enhance protection, comparable to initial vaccine effectiveness. The FDA is anticipated to make its decision soon, potentially marking COMIRNATY as the first COVID-19 booster authorized in the U.S.